Current patient release criteria established in NRB-99/2009 relate to four radionuclides used Russia that period of the document preparation. These were calculated only considering radionuclide decay. Thus, these give conservative assessments which require stay dedicated protected room (“hot” room) radiotherapy department for several days and do not allow therapy be given outpatient hospital ce...

OBJECTIVE The purpose of this paper is to introduce the nuclear medicine technologist to a new radiopharmaceutical, 99mTc-apcitide, for imaging acute venous thrombosis. After reading this paper, the technologist should be able to: (a) describe patient preparation for imaging with 99mTc-apcitide; (b) state the amount of 99mTc-apcitide that is administered to patients for imaging acute venous thr...

UNLABELLED We studied the changing patterns of radiopharmaceutical use and the incidence of adverse events (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and adjunctive nonradioactive pharmaceuticals in nuclear medicine from 2007 to 2011. METHODS Fifteen academic institutions submitted quarterly reports of radiopharmaceutical use and AEs covering 2007-2011. RESULTS 1,024,1...

T hrough its Priority Review mechanism, the U.S. Food and Drug Administration (FDA) recently approved 2 radiopharmaceutical products for use as diagnostic PET agents. The first, approved on May 27, was Axumin (18F-fluciclovine) injection, indicated for use in PET imaging to identify suspected sites of prostate cancer recurrence in men with elevated levels of prostate-specific antigen (PSA) foll...

Identification of sentinel lymph nodes (SLNs) using lymphoscintigraphy, the blue dye technique and intraoperative lymphatic mapping with a gamma-detecting probe has become the standard of care in diagnosing and treating melanoma. Numerous clinical studies have proven the reliability of predicting the histology of remaining lymph nodes in the lymphatic basin from the histologic evaluation of the...

introduction: biodistribution study in animal models bearing tumors is one of the most important procedures in evaluation of fractional uptake of radiopharmaceuticals in the tumor and non-tumor organs. the aim of this study was to develop a new software-based method to determine activities that accumulate in the main organs as well as the tumor based on scintigraphy images, thereby obviating th...

introduction: trastuzumab is a monoclonal antibody that is used in treating breast cancer. we labeled this monoclonal antibody with technetium-99m and performed in vitro and in vivo quality control tests as a first step in the production of a new radiopharmaceutical. methods: trastuzumab was labeled with technetium-99m using succinimidyl hydrazinonicotinamide (hynic) as chelator. radiochemical ...